Skip to content

The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer

The Relationship Between Triceps Skinfold and Overall Survival of Pancreatic Cancer, Cholangiocarcinoma and Gallbladder Cancer.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03637569
Enrollment
1000
Registered
2018-08-20
Start date
2018-04-01
Completion date
2026-12-31
Last updated
2023-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Gallbladder Cancer, Pancreas Cancer

Brief summary

In this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB cancer.

Detailed description

Cachexia is frequently seen in pancreatic cancer(70-80%) and associated with reduced survival, reduced treatment tolerance and reduction in QoL. In recent studies, low-normal BMI have worse outcome (overall mortality) in cardiovascular, malignant, chronic disease (So called obesity paradox) BMI is simple method but hard to define body composition because BMI is based on only weight and height. Skinfold thickness is strongly associated with body fatness than BMI. In this study, the ivestigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB cancer.

Interventions

OTHERMeasurement of triceps skinfold thickness

By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Newly diagnosed pancreatic, bile duct or gallbladder cancer patients, undergoing therapeutic management (including surgery, chemotherapy or palliative care). * Age above 18 years old

Exclusion criteria

* Other malignant disease * Underlying intestinal disease that cause absorprtion disorder * Underlying psychiatric disorder such as eating disorder (bulimia, anorexia)

Design outcomes

Primary

MeasureTime frameDescription
Overall survivalthrough study completion, an average of 2 yearThe duration between diagnosis and death

Countries

South Korea

Contacts

Primary ContactJong-In Chnag, M.D.
ji.chang@samsung.com82-2-3410-3409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026